Ontario Genomics Institute Invests in New Cancer Dx Firm | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Ontario Genomics Institute has invested C$100,000 (US$101,000) in Toronto-based molecular diagnostics developer Rna Diagnostics to support further development of the company's lead test for chemotherapy management.

OGI provided the funding to Rna Diagnostics, which has its research lab in Sudbury, Ontario and uses technology developed at Sudbury's Laurentian University, through its Pre-Commercialization Business Development Fund.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.